Nuvalent Corp - NUVL Quarterly EPS earnings growth

Corporate company logo of Nuvalent (NUVL)

Amidst fierce competition with pharma behemoths, where development speed is everything, the quarterly change in earnings per share helps assess the market prospects of Nuvalent, Inc. (NUVL). The value -17.50 represents the current value of this metric. The issuer relies on partnerships with oncology centers to create precise kinase inhibitors, developing innovative treatments for mutated forms of cancer that are resistant to conventional medications.

nuvalent.com (NUVL) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 07/25/2026

Analytical breakdowns for Nuvalent, Inc.

- share price and consensus valuation forecast:
Fundamental company valuation:nuvalent.com - NUVL
Flagship merchandise of nuvalent.com

Nuvalent, Inc. (NUVL) develops targeted oncology drugs, operating without commercial revenue by relying on investment capital. The absence of revenue makes the earnings per share calculation a derivative of the cash burn rate and operating expenses. This metric measures the dynamics of net income per share on a quarterly basis. Analyzing the quarterly EPS percentage change on GURU.Markets allows for tracking the sustainability of the issuer's financial reserves. Sharp fluctuations in this chart signal risks of accelerated liquidity depletion.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|KYMR (Kymera Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth ideayabio.com|Year-over-year earnings per share growth for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth RLAY (Relay Therapeutics Inc)|Net earnings per share growth for the trailing year Nurix Pharma|Tyra Biosciences Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (immuneering.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Tx CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)